Abstract -Ros1 protein is a receptor tyrosine kinase that has been reported mainly in meningiomas and astrocytomas, and until now, there is n o selective in hibitor for th is kinase. In th is study, we illu strate for the s ynthesis of a highly potent and selective in hibitor for Ros1 kinase. The synthesized compound 1 was tested initially at a single dose concentration of 10 µM over 45 different kinases. At this concentration, a 94% inhibition of the enzymatic activity of Ros1 kinase was observed, while the inhibition in activity was below 30% in all of the other kinases. The p yrazole compound 1 was further tested in a 10-dose IC 50 mode and showed an IC 50 value of 199 nM for Ros1 kinase. Our compound 1 can be used as a promising lead for the development of new selective inhibitors for Ros1 kinase, and it may open the way for new selective therapeutics for astrocytomas.
Signal t ransduction is an e ssential biological process for normal cell growth and function. The transduction of many of t hese s ignals i s m ediated t hrough gr owth factors w hich tr ansmit th eir s ignals in to th e c ell b y a group of trans-membrane p roteins w ith in trinsic tyrosine kinase activity, named receptor tyrosine kinases (RTKs). [1] [2] [3] [4] Mutations a t RTKs e ncoding ge nes a re associated w ith t he i ncidence o f s everal t ypes o f cancers. [5] [6] [7] [8] Ros1 is a human ge ne t hat e ncodes f or a trans-membrane r eceptor tyrosine ki nase. [9] [10] [11] It is located at the chromosome 6 region 6q16→6q22. 9 This region of c hromosome 6 i s i nvolved i n non -random chromosomal ar rangements i n s pecific n eoplasias including a cute l ymphoblastic l eukemias, malignant melanoma, and ovarian carcinoma. 9 A microdeletion at 6q21 of Ros1 results in the fusion of a golgi apparatus associated pr otein c alled F IG ( Fused i n G lioblastoma), to t he ki nase dom ain of t he pr otoncogene Ros1 producing a c himeric pr otein w ith a c onstitutive receptor tyrosine kinase activity.
This fused chimeric protein is a potent oncogene and its transforming potential lies i n its ability to in teract with golgi apparatus. 12 The e ctopic e xpression of Ros1 receptor pr otein has been reported mainly in meningiomas and astrocytomas (25% of l ow gr ade a nd 30% of m alignant gl ioma tumors) suggesting a key role for Ros1 in these CNS malignancies.
12,14 A survey of 45 different human tumor cell lines, made by Birchmeier et al., 11 has showed that Ros1 was expressed in glioblastoma-derived cell lines at high levels, while not expressed at all or expressed minimally in the remaining cell lines.
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Glioblastoma multiforme is the m ost advanced astrocytic ne oplasm, a nd i s one of t he most a ggressive human cancers with a median survival of less than one year. T he c omplete r esection of gl ioblastoma i s impossible be cause of t he di ffuse i nfiltration of tumor cells into normal parenchyma. In addition, these tumors are hi ghly r esistant t o r adiation a nd c hemotherapy. Despite d ecades o f t herapeutic r esearch, ef fective chemotherapeutic treatment for high grade astrocytomas is not yet a vailable, and patient care ultimately focuses on palliative management. [15] [16] [17] [18] Herein, w e r eport the di scovery of a pot ent a nd highly s elective Ros1 RTK in hibitor 1 (Figure 1 ) . T he synthetic an d s creening protocols f or t he i nhibitor are illustrated in d etails. T he ki nase i nhibitory a ctivity of the synthesized c ompound was tested over 45 different kinases, and it showed high selectivity for Ros1 kinase. According to o ur knowledge, th is is th e f irst s elective Ros1 tyrosine kinase inhibitor. For t he s ynthesis of t he t arget c ompound 1, it w as important a t f irst to pr epare t he ke y e ster, methyl 3 -methoxy-5-methylbenzoate ( 5) as illustrated in Scheme 1. The synthesis started with the preparation of the sodium s alt o f e thyl 2 -hydroxy-4-oxopent-2-enoate ( 2) according to lite rature procedure, 19 through t he condensation of diethyl oxalate w ith acetone in the presence of s odium e thoxide i n a bsolute ethanol. T he resulted s alt 2 was t hen c yclized i nto C laisen f uran derivative 3 by heating in 50% acetic acid followed by acidification with sulfuric acid. 20 The resulted C laisen compound un derwent r earrangement a nd a romatization into 3 -hydroxy-5-methylbenzoic aci d ( 4) w ithin le ss than one hour by he ating with magnesium oxi de i n boiling w ater, f ollowed b y a cidification w ith hydrochloric aci d to pr ecipitate t he pr oduct. 20 Methyl esterification a nd O-methylation o f th e r esulted phenolic aci d 4 were a chieved i n a s ingle s tep a nd i n high yield (94%) to give compound 5 through a little modification of t he l iterature pr ocedure, 21 where the acid 4 was r efluxed w ith e xcess pot assium c arbonate and i odomethane i n acet one i n t he p resence of a catalytic amount of DMAP.
In Scheme 2 , the benzoate ester 5 underwent a nucleophilic a ttack a t i ts carboxylic c arbon by t he activated methylene gr oup of 2,4 -dichloro-6-methylpyrimidine. The activation of this methyl group into an active methylene was achieved by dropwise addition of lithium b is(trimethylsilyl)amide ( LHMDS) in d ry T HF at room temperature. The resulted tautomeric α,β-unsaturated ke tone 6 was t hen s ubjected t o a nucleophilic substitution reaction with the amino group of ( S)-(+)-1-aminopropan-2-ol by he ating a t 80 o C i n dry THF for 3 hours. Two regioisomers were produced from this reaction, but the major isomer was (S)-2-(6-(2-hydroxypropyl-amino)-2-chloropyrimidin-4-yl)-1-(3-methoxy-5-methylphenyl)ethanone (7), wh ich wa s separated in a pure form using column chromatography. The st ructure of this isomer was c onfirmed by the 2D -NOESY NM R s pectrum of t he s ubsequent c ompound 10. The conversion of the resulted tautomeric product 7 to t he r equired p yrazole d erivative 8 was ach ieved through t wo su ccessive st eps. I n t he f irst st ep, compound 7 was h eated w ith ex cess N,Ndimethylformamide dimethylacetal for 20 hours, and the resulted pr oduct w as t aken t o t he ne xt s tep w ithout further p urification, w here it w as c yclized w ith hydrazine m onohydrate i n a bsolute e thanol i nto t he pyrazole d erivative 8. T he r eaction of t he r esulted pyrazole 8 with io doacetonitrile in the p resence o f excess pot assium c arbonate pr oduced t wo di fferent regioisomers. T he i ntended i somer 9 was th e m ajor product of t he r eaction w ith R f value of 0.54 ( EtOAc) while the other isomer was produced as a minor product with hi gher R f value of 0.66 ( EtOAc). T he r equired isomer 9 was s eparated i n a p ure f orm b y co lumn chromatography and its structure was confirmed by 2D-NOESY NM R s pectrum of t he s ubsequent c ompound 10. C ompound 10 was prepared i n a m oderate y ield (67%) by S uzuki c oupling of c ompound 9 with 3 -pyridineboronic a cid, i n the pr esence of di chloro bis(triphenylphosphine)Pd(II) and sodium c arbonate, in a mixed solvent of acetonitrile and water in a (1:1) ratio. The 2D -NOESY NM R spectrum of t his c ompound confirmed the former nucleophilic substitution with (S)-(+)-1-aminopropan-2-ol in compound 7 at the 6-position of t he py rimidine r ing ( not t he 2 -position). T his w as proved by the absence of a cross peak between H 5 of the pyrimidine r ing a nd H 2 or H 4 of t he py ridyl gr oup (Figure 2a The pr esence of s uch c ross peak w ould b e e xpected i f the s ubstitution w ith (S)-(+)-1-aminopropan-2-ol occurred at the C 2 of the pyrimidine, since in this case, the subsequent substitution with pyridin-3-yl m oiety would happen at the 6 position of pyrimidine, allowing through space interaction between H 5 of the pyrimidine and H 2 or H 4 of the pyridine (Figure 2b) . Furthermore, the presence of a cross peak between pyrimidine H 5 and the NH of the aminopropan-2-ol provides another evidence f or t he pr esence of t he a minopropan-2-ol group a t t he 6 pos ition of t he py rimidine r ing ( Figure  2a) . It was important also to prove that the former isomer 9 is t he i ntended 1H -pyrazole not t he 2H -pyrazole. This was proved too by the 2D-NOESY NMR spectrum of compound 10, by the absence of any cross peak t hat m ight i ndicate a t hrough s pace i nteraction between the -CH 2 -protons of the acetonitrile group and any of t he a romatic pr otons of t he 3 -methoxy-5-methylphenyl gr oup ( Figure 2c ). T he pr esence of s uch cross-peaks would be expected if this isomer is the 2H-pyrazole, s ince t he a cetonitrile gr oup w ould be c lose enough t o t he a romatic pr otons of 3 -methoxy-5-methylphenyl group to exhibit NOE effect as shown in Figure 2d . The f inal hy droxyl pr oduct 1 was o btained by d emethylation of t he m ethoxy gr oup of c ompound 10 using 10 equivalents of bor ontrifluoridedimethylsulfide complex in dichloromethane. The sc reening r esults of the target c ompound 1 over 45 di fferent ki nases h ave r evealed t hat t he inhibitory activity of the compound was not exhibited over almost all of the tested kinases, while high potency and activity was selectively shown at Ros1 kinase only (Table 1) . The c ompound w as t ested initially at a s ingle d ose concentration of 10 µM. At this concentration, a 93.92% inhibition of the enzymatic activity of Ros1 kinase was observed, w hile t he i nhibition i n a ctivity w as be low 30% in all of the other kinases, and in the range of 20-30% i n 5 ki nases only (ABL1, Aurora A , E PHA1, RAF1 & RON/MST1R).
Compound 1 was fu rther t ested o ver R os1 k inase i n order to determine its IC 50 , where a 10-dose IC 50 mode with 3 f old s erial d ilutions s tarting a t 2 0 µ M concentration w as a pplied a gainst S taurosporine [22] [23] [24] as a r eference s tandard ( Figure 3) . The c ompound h as showed a n IC 50 value of 199 nM , while the IC 50 value for the non-selective kinase inhibitor Staurosporine was 0.07 nM. The hi gh s electivity of c ompound 1 to R os1 ki nase and the diminished activity over the other kinases could be a ttributed t o t he i ncreased bul kiness exerted by t he sbstituents a t pyrimidine nucleus. T his i ncrease i n bulkiness seems to hinder the fitting of the compound to the binding sites of most of these kinases and to exclude it f rom t heir bi nding poc kets. H owever, t he s elective inhibition of R os1 ki nase m ight be ow ed t o a uni que difference in the geometry of the binding pocket of this enzyme that e nables t he fitting a nd i nteraction of compound 1. An indirect inhibitory effect of compound 1 at Ros1 ki nase, pr obably t hrough bi nding a t a n allosteric bi nding s ite, i s a nother pos sible a ssumption for t he r eason behind t his s elective i nhibition. T he absolute r eason i s s till u nclear an d w e b elieve that i t worth f urther e xploration f or t he m echanism of i ts unique inhibitory effect.
In conclusion, a highly potent and selective inhibitor for Ros1 kinase has been synthesized and can be used as a pr omising l ead f or ne w s elective i nhibitors f or R os1 kinase. It worth also to mention that until now, no selective inhibitor is a vailable for Ros1 kinase, and the development of new selective inhibitors for such kinase might o pen t he w ay f or n ew s elective t herapeutics f or astrocytomas. S creening of c ompound 1 against glioblastoma derived tumors is currently undergoing.
